Mizuho Keeps Outperform Rating on Align, Medline and Tesla
Mizuho maintained Outperform ratings on Align Technology, Medline and Tesla, cutting targets for the first two and raising the target for Tesla. Source: Dow Jones Newswires.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Mizuho analysts kept their Outperform rating on three companies at once. For Align Technology (ALGN), the price target was lowered to $200 per share from $220. For Medline (MDLN), the target was cut to $45 from $48, with the rating unchanged. For Tesla (TSLA), the price target was raised to $460 from $450, and the rating also stayed the same.
The report was published by Dow Jones Newswires, citing data from Benzinga. The actions were recorded on October 22, 2026, at 12:02, 12:04 and 12:19 GMT.
why it matters
Target price changes reflect a revised view from one analyst on individual companies and usually affect only their shares, with little effect on broad indices. For Tesla investors, the higher target means the bank's valuation edged up, while the forecast for Align and Medline was reduced even though the positive rating held.
tags
instruments
sources
- Align Technology Is Maintained at Outperform by Mizuho — Dow Jones Newswires, 22 October 2026 at 12:02 UTC
- Medline Is Maintained at Outperform by Mizuho — Dow Jones Newswires, 22 October 2026 at 12:04 UTC
- Tesla Is Maintained at Outperform by Mizuho — Dow Jones Newswires, 22 October 2026 at 12:19 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗